Hunter VJ - Search Results

1

The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer.

Drisko JA, Chapman J, Hunter VJ. Drisko JA, et al. Among authors: hunter vj. J Am Coll Nutr. 2003 Apr;22(2):118-23. doi: 10.1080/07315724.2003.10719284. J Am Coll Nutr. 2003. PMID: 12672707

2

The use of antioxidant therapies during chemotherapy.

Drisko JA, Chapman J, Hunter VJ. Drisko JA, et al. Among authors: hunter vj. Gynecol Oncol. 2003 Mar;88(3):434-9. doi: 10.1016/s0090-8258(02)00067-7. Gynecol Oncol. 2003. PMID: 12648599 Review.

3

Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).

Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS. Rothenberg ML, et al. Among authors: hunter vj. Gynecol Oncol. 2001 Aug;82(2):317-22. doi: 10.1006/gyno.2001.6274. Gynecol Oncol. 2001. PMID: 11531286 Clinical Trial.

4

The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction.

Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC Jr. Hunter VJ, et al. Am J Obstet Gynecol. 1990 Oct;163(4 Pt 1):1164-7. doi: 10.1016/0002-9378(90)90680-6. Am J Obstet Gynecol. 1990. PMID: 2171337

5

Reduction of tumor necrosis factor-alpha bioactivity by a human ovarian epithelial cancer cell line in vitro.

Sancho-Tello M, Marcinkiewicz JL, Justice WM, Kimler BF, Terranova PF, Hunter VJ. Sancho-Tello M, et al. Among authors: hunter vj. Am J Obstet Gynecol. 1995 Nov;173(5):1470-7. doi: 10.1016/0002-9378(95)90635-5. Am J Obstet Gynecol. 1995. PMID: 7503187

6

Epithelial ovarian tumors of low malignant potential.

Massad LS Jr, Hunter VJ, Szpak CA, Clarke-Pearson DL, Creasman WT. Massad LS Jr, et al. Among authors: hunter vj. Obstet Gynecol. 1991 Dec;78(6):1027-32. Obstet Gynecol. 1991. PMID: 1945202 Review.

7

CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer.

Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC Jr. Hunter VJ, et al. Gynecol Oncol. 1990 Feb;36(2):161-5. doi: 10.1016/0090-8258(90)90165-h. Gynecol Oncol. 1990. PMID: 2404835

8

Peritoneal papillary serous carcinoma in a woman with a history of utero DES exposure.

Seoud MA, Tawfik O, Hunter V. Seoud MA, et al. Gynecol Oncol. 1993 Sep;50(3):371-3. doi: 10.1006/gyno.1993.1228. Gynecol Oncol. 1993. PMID: 8406204

9

Tumor necrosis factor-alpha alters steroidogenesis and stimulates proliferation of human ovarian granulosal cells in vitro.

Yan Z, Hunter V, Weed J, Hutchison S, Lyles R, Terranova P. Yan Z, et al. Fertil Steril. 1993 Feb;59(2):332-8. doi: 10.1016/s0015-0282(16)55676-3. Fertil Steril. 1993. PMID: 8425627 Free article.

10

Tumor necrosis factor-alpha in the female reproductive tract.

Terranova PF, Hunter VJ, Roby KF, Hunt JS. Terranova PF, et al. Among authors: hunter vj. Proc Soc Exp Biol Med. 1995 Sep;209(4):325-42. doi: 10.3181/00379727-209-43905b. Proc Soc Exp Biol Med. 1995. PMID: 7638240 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

20 results

Search Page